EcoR1 Capital LLC cut its position in FibroGen, Inc (NASDAQ:FGEN) by 93.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 42,009 shares of the biopharmaceutical company’s stock after selling 644,175 shares during the period. FibroGen comprises approximately 0.3% of EcoR1 Capital LLC’s investment portfolio, making the stock its 25th largest position. EcoR1 Capital LLC’s holdings in FibroGen were worth $1,036,000 as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of the company. Woodstock Corp increased its stake in FibroGen by 42.9% in the first quarter. Woodstock Corp now owns 28,415 shares of the biopharmaceutical company’s stock worth $700,000 after buying an additional 8,526 shares in the last quarter. Teachers Advisors LLC raised its stake in shares of FibroGen by 3.7% in the fourth quarter. Teachers Advisors LLC now owns 461,901 shares of the biopharmaceutical company’s stock worth $9,885,000 after buying an additional 16,544 shares during the period. Norges Bank bought a new stake in shares of FibroGen during the fourth quarter worth about $8,480,000. Tudor Investment Corp Et Al bought a new stake in shares of FibroGen during the fourth quarter worth about $376,000. Finally, Bogle Investment Management L P DE bought a new stake in shares of FibroGen during the fourth quarter worth about $2,231,000. 44.08% of the stock is currently owned by institutional investors.
Shares of FibroGen, Inc (NASDAQ FGEN) traded up 1.53% during midday trading on Friday, hitting $29.80. The stock had a trading volume of 822,104 shares. The stock has a 50 day moving average price of $27.85 and a 200-day moving average price of $24.85. The stock’s market capitalization is $2.08 billion. FibroGen, Inc has a 52 week low of $14.50 and a 52 week high of $29.80.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.11. FibroGen had a negative return on equity of 36.41% and a negative net margin of 37.60%. The business had revenue of $26.89 million during the quarter, compared to analyst estimates of $26.02 million. Equities research analysts anticipate that FibroGen, Inc will post ($1.81) earnings per share for the current year.
Separately, Zacks Investment Research lowered FibroGen from a “hold” rating to a “sell” rating in a research report on Monday, May 8th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $37.50.
In related news, VP Pat Cotroneo sold 6,500 shares of the business’s stock in a transaction that occurred on Tuesday, April 25th. The stock was sold at an average price of $28.00, for a total transaction of $182,000.00. Following the completion of the transaction, the vice president now owns 164,405 shares in the company, valued at approximately $4,603,340. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Toshinari Tamura sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $28.89, for a total value of $866,700.00. Following the transaction, the director now owns 60,000 shares of the company’s stock, valued at approximately $1,733,400. The disclosure for this sale can be found here. Insiders have sold a total of 359,907 shares of company stock valued at $9,463,826 in the last 90 days. Insiders own 14.90% of the company’s stock.
FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen, Inc (NASDAQ:FGEN).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/fibrogen-inc-fgen-shares-sold-by-ecor1-capital-llc/1916390.html
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.